Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 616,858 | 278,446 | 1,059,464 | 811,276 | 536,666 |
| Depreciation Amortization | 78,734 | 37,683 | 145,183 | 106,462 | 69,835 |
| Income taxes - deferred | 20,428 | 13,890 | 131,204 | 99,675 | 6,427 |
| Accounts receivable | -82,844 | -56,808 | -68,722 | -82,586 | -74,889 |
| Accounts payable and accrued liabilities | 4,481 | 11,217 | -8,573 | -4,977 | -12,113 |
| Other Working Capital | -146,688 | -89,748 | -227,514 | -244,493 | -224,543 |
| Other Operating Activity | 122,441 | 71,568 | 150,763 | 140,688 | 122,322 |
| Operating Cash Flow | $613,410 | $266,248 | $1,181,805 | $826,045 | $423,705 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,282 | 240 | 1,987 | 483 | 890 |
| PPE Investments | -56,630 | -31,984 | -124,676 | -95,242 | -64,128 |
| Purchase Sale Intangibles | -3,692 | -1,800 | -13,550 | -13,350 | N/A |
| Other Investing Activity | -3,692 | -1,800 | -13,550 | -13,350 | 0 |
| Investing Cash Flow | $-59,040 | $-33,544 | $-136,239 | $-108,109 | $-63,238 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 121,000 | 132,000 | N/A | 205,000 | 329,000 |
| Debt Issued | N/A | N/A | 250,000 | N/A | N/A |
| Debt Repayment | N/A | N/A | -428,385 | -103,386 | -103,386 |
| Common Stock Issued | 51,074 | 18,161 | 93,362 | N/A | 24,523 |
| Common Stock Repurchased | -708,693 | -361,591 | -1,224,203 | -986,369 | -746,089 |
| Other Financing Activity | 0 | 0 | 144,262 | 75,493 | 0 |
| Financing Cash Flow | $-536,619 | $-211,430 | $-1,164,964 | $-809,262 | $-495,952 |
| Exchange Rate Effect | -888 | -816 | 11,202 | 11,226 | 11,813 |
| Beginning Cash Position | 180,070 | 180,070 | 288,266 | 288,266 | 288,266 |
| End Cash Position | 196,933 | 200,528 | 180,070 | 208,166 | 164,594 |
| Net Cash Flow | $16,863 | $20,458 | $-108,196 | $-80,100 | $-123,672 |
| Free Cash Flow | |||||
| Operating Cash Flow | 613,410 | 266,248 | 1,181,805 | 826,045 | 423,705 |
| Capital Expenditure | -56,630 | -31,984 | -124,676 | -95,242 | -64,128 |
| Free Cash Flow | 556,780 | 234,264 | 1,057,129 | 730,803 | 359,577 |